ZA914165B - Pharmacologically active CNS compounds. - Google Patents

Pharmacologically active CNS compounds.

Info

Publication number
ZA914165B
ZA914165B ZA914165A ZA914165A ZA914165B ZA 914165 B ZA914165 B ZA 914165B ZA 914165 A ZA914165 A ZA 914165A ZA 914165 A ZA914165 A ZA 914165A ZA 914165 B ZA914165 B ZA 914165B
Authority
ZA
South Africa
Prior art keywords
hydrogen
halo
alkyl
compounds
pharmacologically active
Prior art date
Application number
ZA914165A
Other languages
English (en)
Inventor
Michael John Leach
Malcolm Stuart Nobbs
Ramachandran Iyer
Clive Leonard Yeates
Philip Alan Skone
Original Assignee
Wellcom Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcom Foundation Limited filed Critical Wellcom Foundation Limited
Publication of ZA914165B publication Critical patent/ZA914165B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Paper (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA914165A 1990-06-01 1991-05-30 Pharmacologically active CNS compounds. ZA914165B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (1)

Publication Number Publication Date
ZA914165B true ZA914165B (en) 1993-03-01

Family

ID=10676964

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA914165A ZA914165B (en) 1990-06-01 1991-05-30 Pharmacologically active CNS compounds.

Country Status (25)

Country Link
EP (2) EP0459819B1 (index.php)
JP (1) JPH06340634A (index.php)
KR (1) KR920000733A (index.php)
AT (1) ATE141263T1 (index.php)
AU (2) AU652753B2 (index.php)
CA (1) CA2043640A1 (index.php)
CZ (1) CZ281070B6 (index.php)
DE (1) DE69121317T2 (index.php)
DK (1) DK0459819T3 (index.php)
ES (1) ES2093078T3 (index.php)
FI (1) FI912623A7 (index.php)
GB (1) GB9012316D0 (index.php)
GR (1) GR3021237T3 (index.php)
HU (2) HUT58707A (index.php)
IE (1) IE911861A1 (index.php)
IL (2) IL113599A (index.php)
MY (2) MY109958A (index.php)
NO (1) NO180375C (index.php)
NZ (3) NZ272001A (index.php)
PL (2) PL170373B1 (index.php)
PT (1) PT97827B (index.php)
RU (1) RU2091374C1 (index.php)
SK (1) SK278444B6 (index.php)
TW (1) TW224460B (index.php)
ZA (1) ZA914165B (index.php)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
FI20021701A7 (fi) * 1991-01-30 2002-09-24 The Wellcome Foundation Ltd Veteen dispergoituvia tabletteja
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
EP0674627A1 (en) * 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
KR100532546B1 (ko) 1999-09-16 2005-12-01 다나베 세이야꾸 가부시키가이샤 방향족 질소 함유 6-원 고리 화합물
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
US7220736B2 (en) 2000-04-28 2007-05-22 Tanabe Seiyaku Co., Ltd. Pyrimidine compounds
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
WO2002008205A1 (en) * 2000-07-24 2002-01-31 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
CA2438294C (en) 2001-02-26 2008-10-21 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
MXPA04007612A (es) * 2002-02-05 2004-11-10 Novo Nordisk As Aril- y heteroarilpiperazinas novedosas.
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
ATE536344T1 (de) 2005-07-04 2011-12-15 High Point Pharmaceuticals Llc Histamine h3 receptor antagonisten
CA2653062A1 (en) 2006-05-23 2007-11-29 Transtech Pharma, Inc. 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
MX2008014766A (es) 2006-05-29 2009-03-06 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)-piperazi na, sus sales y solvatos y su uso como antagonista del receptor de h3 histamina.
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
CN106831732B (zh) * 2011-06-10 2019-12-24 默克专利有限公司 生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
CA3023216A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
US20190343836A1 (en) 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (index.php) *
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
NO180375B (no) 1996-12-30
DE69121317T2 (de) 1997-01-02
AU6745594A (en) 1994-09-15
AU680252B2 (en) 1997-07-24
FI912623A0 (fi) 1991-05-31
IL113599A (en) 1997-09-30
AU7809791A (en) 1991-12-05
KR920000733A (ko) 1992-01-29
PL170373B1 (pl) 1996-12-31
FI912623A7 (fi) 1991-12-02
NO912100L (no) 1991-12-02
IE911861A1 (en) 1991-12-04
GB9012316D0 (en) 1990-07-18
AU652753B2 (en) 1994-09-08
CZ281070B6 (cs) 1996-06-12
IL113599A0 (en) 1995-08-31
DE69121317D1 (de) 1996-09-19
TW224460B (index.php) 1994-06-01
PL166656B1 (pl) 1995-06-30
CS164391A3 (en) 1992-02-19
ATE141263T1 (de) 1996-08-15
ES2093078T3 (es) 1996-12-16
MY109958A (en) 1997-10-31
EP0459819A2 (en) 1991-12-04
RU2091374C1 (ru) 1997-09-27
EP0459819A3 (en) 1992-03-11
CA2043640A1 (en) 1991-12-02
DK0459819T3 (da) 1996-09-02
PT97827A (pt) 1992-03-31
SK278444B6 (en) 1997-05-07
HU911826D0 (en) 1991-12-30
EP0459819B1 (en) 1996-08-14
NZ272001A (en) 1997-03-24
NZ248501A (en) 1997-03-24
GR3021237T3 (en) 1997-01-31
HU211649A9 (en) 1995-12-28
NO912100D0 (no) 1991-05-31
IL98330A0 (en) 1992-06-21
EP0679645A1 (en) 1995-11-02
JPH06340634A (ja) 1994-12-13
NO180375C (no) 1997-04-09
NZ238360A (en) 1997-03-24
MY136248A (en) 2008-08-29
HUT58707A (en) 1992-03-30
IL98330A (en) 1996-10-31
PT97827B (pt) 1998-10-30

Similar Documents

Publication Publication Date Title
EP0459819A3 (en) Pharmacologically active cns compounds
FI89709B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara arylderivat
HUP9901113A1 (hu) Herbicid hatású és növényi növekedést szabályozó hatású 2-amino-4-biciklo-amino-1,3,5-triazinok
HUT59562A (en) Cys-carboxamide derivatives, process for producing them and herbicide compositions containing them
HU896723D0 (en) Process for preparation of guanidine-derivatives and insecticid compositions comprising these compounds as active ingredient
PH25859A (en) Composition for treatment of ischemic disorder
HUT54667A (en) Process for producing alkyl-substituted piperazine derivatives and pharmaceutical compositions containing them
BR8502972A (pt) Processo para a preparacao de 5-amino-4-heterociclil-1-fenilpirazois,composicoes herbicidas,aplicacao,processos para a preparacao de composicoes e para a preparacao de derivados de acrilonitrila
IL86462A (en) Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
ES8708136A1 (es) Procedimiento para la obtencion de derivados de acido barbiturico
MY109714A (en) Process for preparing 8-chloroquinolone derivatives
ATE205209T1 (de) Chinolincarbonsäurederivate und ihre salze
ZA882374B (en) Biologically active compounds
ES8608500A1 (es) Un procedimiento para preparar nuevas 1,2,4-tiadiazinas
HU9600597D0 (en) 4-alkylthio-pyrimidin-5-yl acetic acid derivates and fungicidal compositions containing them as an active ingredient
NO954109L (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte 5-arylpyrimidiner
MY104630A (en) 4(1h) ouinoline derivatives
GB8829817D0 (en) Benzamide compounds,their preparation and their use as pesticides
DE3464053D1 (en) Pyrazine compounds, their preparation and their use, compositions containing them and method of combating undesired plant growth